Market report: Anagen makes comeback
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.ANAGEN, a failed drugs business, is making a market comeback. It is taking over Gander, a property group, in a share exchange deal which will allow Gander to use Anagen's pounds 27m of losses to offset future profits. Anagen was delisted last year and is now a shell.
William Cairns, who put up the sum of pounds 200,000 to save the company from liquidation, will have 3 per cent of the combined group. Gander's share price rose 0.25p to 7p.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments